319 related articles for article (PubMed ID: 8313392)
21. Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.
Fisar Z; Hroudová J; Raboch J
Neuro Endocrinol Lett; 2010; 31(5):645-56. PubMed ID: 21200377
[TBL] [Abstract][Full Text] [Related]
22. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
Zimmer R
Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
[TBL] [Abstract][Full Text] [Related]
23. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
Bieck PR; Antonin KH
J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
[TBL] [Abstract][Full Text] [Related]
24. cAMP-dependent phosphorylation system after short and long-term administration of moclobemide.
Mori S; Zanardi R; Popoli M; Garbini S; Brunello N; Smeraldi E; Racagni G; Perez J
J Psychiatr Res; 1998; 32(2):111-5. PubMed ID: 9694007
[TBL] [Abstract][Full Text] [Related]
25. Effect of moclobemide on rat brain monoamine oxidase A and B: comparison with harmaline and clorgyline.
Gerardy J
Prog Neuropsychopharmacol Biol Psychiatry; 1994 Jul; 18(4):793-802. PubMed ID: 7938567
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of 5-HT-induced anorexia: a test of the reversibility of monoamine oxidase inhibitors.
Fletcher PJ; Yu PH
Psychopharmacology (Berl); 1989; 98(2):265-8. PubMed ID: 2502797
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
Burkard WP; Bonetti EP; Da Prada M; Martin JR; Polc P; Schaffner R; Scherschlicht R; Hefti F; Müller RK; Wyss PC
J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
[TBL] [Abstract][Full Text] [Related]
28. Reversible monoamine oxidase-A inhibitors in resistant major depression.
Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
[TBL] [Abstract][Full Text] [Related]
29. RIMA: a safe concept in the treatment of depression with moclobemide.
Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
[TBL] [Abstract][Full Text] [Related]
30. Studies of selective and reversible monoamine oxidase inhibitors.
Mann JJ; Aarons SF; Frances AJ; Brown RD
J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
[TBL] [Abstract][Full Text] [Related]
31. Effect of co-administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular monoamine levels and the expression of contextual conditioned fear in rats.
Kitaichi Y; Inoue T; Nakagawa S; Izumi T; Koyama T
Eur J Pharmacol; 2006 Feb; 532(3):236-45. PubMed ID: 16487506
[TBL] [Abstract][Full Text] [Related]
32. Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.
Möller HJ; Wendt G; Waldmeier P
Pharmacopsychiatry; 1991 Mar; 24(2):50-4. PubMed ID: 1852792
[TBL] [Abstract][Full Text] [Related]
33. Effects of co-administration of antidepressants and monoamine oxidase inhibitors on 5-HT-related behavior in rats.
Izumi T; Iwamoto N; Kitaichi Y; Kato A; Inoue T; Koyama T
Eur J Pharmacol; 2007 Jun; 565(1-3):105-12. PubMed ID: 17400208
[TBL] [Abstract][Full Text] [Related]
34. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
Waldmeier PC
Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
[TBL] [Abstract][Full Text] [Related]
35. Some basic aspects of reversible inhibitors of monoamine oxidase-A.
Da Prada M; Kettler R; Burkard WP; Lorez HP; Haefely W
Acta Psychiatr Scand Suppl; 1990; 360():7-12. PubMed ID: 2248079
[TBL] [Abstract][Full Text] [Related]
36. [Effect of benzamide derivatives on convulsions induced by the toxic action of oxygen in rats].
Gol'dina OA; Tepliakov VG; Demurov EA; Koloskov IuB; Zagorevskiĭ VA
Biull Eksp Biol Med; 1987 Oct; 104(10):469-71. PubMed ID: 3676473
[TBL] [Abstract][Full Text] [Related]
37. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
Dyck LE; Boulton AA
Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
[TBL] [Abstract][Full Text] [Related]
38. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies.
Delini-Stula A; Baier D; Kohnen R; Laux G; Philipp M; Scholz HJ
Pharmacopsychiatry; 1999 Mar; 32(2):61-7. PubMed ID: 10333164
[TBL] [Abstract][Full Text] [Related]
39. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
Lotufo-Neto F; Trivedi M; Thase ME
Neuropsychopharmacology; 1999 Mar; 20(3):226-47. PubMed ID: 10063483
[TBL] [Abstract][Full Text] [Related]
40. Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase.
Finberg JP; Youdim MB
J Neural Transm Suppl; 1988; 26():11-6. PubMed ID: 3162950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
